Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

Resistance to Tau and Amyloid Pathology Facilitates Super-Aging

Merle Hoenig, Gerard Bischof, Niclas Willscheid, Thilo van Eimeren, Alexander Drzezga and for the Alzheimer’s Disease Neuroimaging Initiative
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 20;
Merle Hoenig
2Institute for Neuroscience and Medicine II - Molecular Organization of the Brain Research Center Juelich Juelich Germany
1University Hospital Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Bischof
1University Hospital Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niclas Willscheid
1University Hospital Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thilo van Eimeren
1University Hospital Cologne Cologne Germany
3German Center for Neurodegenerative Diseases Bonn/Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Drzezga
3German Center for Neurodegenerative Diseases Bonn/Cologne Germany
1University Hospital Cologne Cologne Germany
2Institute for Neuroscience and Medicine II - Molecular Organization of the Brain Research Center Juelich Juelich Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
for the Alzheimer’s Disease Neuroimaging Initiative
1University Hospital Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

20

Objectives: The phenomenon of selected individuals cognitively performing above the norm even at high age (so-called super-agers) suggests that these individuals must obtain extraordinary resistance mechanisms against brain aging processes and/or neurodegeneration. However, not much is known about age-associated molecular hallmarks of neurodegeneration in super-agers, particularly concerning proteinopathies such as the accumulation of amyloid-β and tau. Therefore, we compared the intracerebral amyloid and tau burden in vivo in a group of super-agers (SA), normal-agers (NA) and patients with mild cognitive impairment (MCI) using PET imaging.

Methods: Data used for analysis were retrieved from the Alzheimer’s Disease Neuroimaging Initiative database (http://adni.loni.usc.edu/) and included three age- and education-matched groups of 26 SA, 25 NA and 25 MCI patients, all above 80 years of age. SA were defined as individuals performing above a z-score of 1.5 over a four-year period including the time-point of the PET scan acquisitions. NA presented average (0.5 < z-score > 1.5) and MCI patients below average (z-score < 0) cognitive performance in this time period. In addition, 18 younger cognitively-normal, amyloid-negative controls (YA; M(Age)= 63.2 years) were included as reference group. [18F]AV-1451 and [18F]AV-45 scans were available for all individuals. The PET scans were pre-processed including normalization to MNI space, smoothing and intensity standardization to the cerebellum. For statistical analysis, voxel-wise comparisons (p < .001, uncorr.) and a region-of-interest (ROI) analysis (p < .05) were conducted, comparing tau and amyloid burden between the four groups, respectively. Moreover, a logistic regression was performed to identify genetic and pathophysiological factors best predicting the different aging processes.

Results: No significant differences between SA and YA were observed in terms of in vivo tau and amyloid burden. The NA group exhibited higher tau burden in inferior temporal and precuneal areas and no significant differences in amyloid burden, when compared to the YA group. The MCI patients showed both high amyloid and tau pathology burden. Differences in amyloid burden predicted NA from MCI, whereas lower tau burden and lower polygenic risk predicted SA from MCI.

Conclusions: The phenomenon of super-aging appears to be associated with the resistance to tau and amyloid pathology, which likely permits maintenance of cognitive performance despite advanced age. In turn, differences between normal aging and MCI appear to be driven by the level of amyloid burden. These results motivate further research to determine responsible resistance factors, which may also inspire the development of novel treatment concepts.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Resistance to Tau and Amyloid Pathology Facilitates Super-Aging
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Resistance to Tau and Amyloid Pathology Facilitates Super-Aging
Merle Hoenig, Gerard Bischof, Niclas Willscheid, Thilo van Eimeren, Alexander Drzezga, for the Alzheimer’s Disease Neuroimaging Initiative
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 20;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Resistance to Tau and Amyloid Pathology Facilitates Super-Aging
Merle Hoenig, Gerard Bischof, Niclas Willscheid, Thilo van Eimeren, Alexander Drzezga, for the Alzheimer’s Disease Neuroimaging Initiative
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 20;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • Brain-related complications of COVID-19 and the role of FDG-PET in detecting vascular and non-vascular defects throughout the body
  • A critical review of the utility of PET imaging in the diagnosis and management of psychosis
  • The radiological study of traumatic brain injury: an emphasis upon molecular imaging
Show more Neurosciences

Brain Imaging Council YIA Symposium

  • Visualization of Flortaucipir Retention in Subjects Grouped According to their Autopsy-Confirmed Neurofibrillary Tangle Scores
  • Machine learning-derived multimodal neuroimaging of presurgical target area to predict individual’s seizure outcomes after epilepsy surgery
  • Visualizing innate immune activation in a mouse model of Parkinson’s disease using a highly specific TREM1-PET tracer.
Show more Brain Imaging Council YIA Symposium

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire